Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience

Natalie C Ward; Jing Pang; Jacqueline D M Ryan; Gerald F Watts

doi:10.1002/clc.22862

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience

Clin Cardiol. 2018 Jan;41(1):159-165. doi: 10.1002/clc.22862. Epub 2018 Jan 24.

Authors

Natalie C Ward^{1

2}, Jing Pang^{1

3}, Jacqueline D M Ryan^{1

4}, Gerald F Watts^{1

3}

Affiliations

¹ School of Medicine, Faculty of Health & Medical Sciences, University of Western Australia, Perth.
² School of Biomedical Sciences and Curtin Health Innovation Research Institute, Perth, Australia.
³ Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia.
⁴ Perth Lipid Clinic, Primary Care, Perth, Australia.

Abstract

There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.

Keywords: Low-Density Lipoprotein Cholesterol; Nutraceuticals; SAMS; Statin Myopathy.

Publication types

Review

MeSH terms

Cardiovascular Diseases / therapy*
Dietary Supplements*
Disease Management*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Muscle, Skeletal / drug effects*
Muscular Diseases / chemically induced*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors